The optimal use of bexarotene in cutaneous T‐cell lymphoma

  title={The optimal use of bexarotene in cutaneous T‐cell lymphoma},
  author={Robert Gniadecki and Chalid Assaf and Martine Bagot and Reinhard Dummer and Madeleine Duvic and Robert Knobler and Annamari Ranki and Peter Schwandt and Sean J. Whittaker},
  journal={British Journal of Dermatology},
The management goal in cutaneous T‐cell lymphomas (CTCLs) is to improve symptoms and induce remission. Early‐stage disease is generally treated with skin‐directed therapies. However, if these do not control the disease, systemic therapy becomes necessary. Bexarotene, a novel rexinoid, is an oral, noncytotoxic drug that has been approved in Europe for the treatment of refractory advanced‐stage CTCL and in the U.S.A. for refractory CTCL. We provide guidance on the use of bexarotene in the… 

Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.

It is concluded that the dose of bexarotene should be titrated individually to achieve optimal results and maintenance therapy with low-dose bexARotene is a feasible alternative.

Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma

Based on the results of the analysis, bexarotene is a valuable tool in the treatment of refractory early-stage CTCL, although a majority of patients initially responded to therapy, the high mortality rate in the advanced-stage group suggests that bexARotene does not completely resolve the therapeutic problems in all stages of CTCC.

Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides.

The aim of this paper is to review bexarotene action on CTCLs, as well as to highlight its immunological targets.

Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management.

  • R. Wilcox
  • Medicine
    American journal of hematology
  • 2017
Patients with advanced-stage disease with significant nodal, visceral or blood involvement are generally approached with biologic-response modifiers or histone deacetylase inhibitors prior to escalating therapy to include systemic, single-agent chemotherapy.

Recent advances in the management of cutaneous lymphomas.

This work aims to summarize new and emerging treatment modalities, and to outline how they may be integrated into the clinical management of patients with primary cutaneous lymphoma.

U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T‐cell lymphoma

Bexarotene has activity in cutaneous T‐cell lymphoma (CTCL) and has been approved by the European Medicines Agency since 1999 for treatment of the skin manifestations of advanced‐stage CTCL in adult patients refractory to at least one systemic treatment.

How I treat mycosis fungoides and Sézary syndrome.

Treatment of early-stage disease (IA-IIA) typically involves skin directed therapies that include topical corticosteroids, phototherapy (psoralen plus ultraviolet A radiation or ultraviolet B radiation), topical chemotherapy, topical or systemic bexarotene, and radiotherapy.

How I Treat How I treat mycosis fungoides and Sézary syndrome

This review focuses on mycosis fungoides and its leukemic variant, Sézary syndrome, and the diagnosis of MF/SS, which has an excellent prognosis but the prognosis for patients presenting with advancedstage disease is poor.

Therapy of Sézary syndrome

This review will focus on this interesting and expanding group of treatments, such as interferons, retinoids, extracorporeal photopheresis and combination therapy, which are first-line therapies due to their favorable side-effect profiles and second-line treatments owing to the risk of iatrogenic immunosuppression and cumulative toxicity.

Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome.

  • M. Duvic
  • Medicine, Biology
    Hematology. American Society of Hematology. Education Program
  • 2015
Mycosis fungoides is the most common variant of cutaneous T-cell lymphomas among the EORTC-ISCL classification and their skin lesions can be well controlled using skin-directed therapies.



Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series.

Topical and systemic retinoid therapy for cutaneous T-cell lymphoma.

Minimizing adverse side‐effects of oral bexarotene in cutaneous T‐cell lymphoma: an expert opinion

The strategy anticipates that these common adverse events are likely to occur and recommends the early use of preventive therapy to lower triglycerides and elevate thyroid hormone levels in the blood, followed by subsequent monitoring, dose adjustment during bexarotene treatment, and titration of the daily bexARotene dose, which is optimal for most patients.

Interferon treatment of cutaneous T‐cell lymphoma

The clinical stage of disease before treatment is the only known predictive parameter concerning the clinical response to IFN treatment in patients with CTCL, and continuous low‐dose IFN therapy, presumably in combination with psoralen and UVA light (PUVA), is recommended.

Optimizing bexarotene therapy for cutaneous T-cell lymphoma.

  • S. E. Whitmore
  • Medicine
    Journal of the American Academy of Dermatology
  • 2004

Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.

  • M. DuvicK. Hymes R. Yocum
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
Bexarotene is orally administered, safe, and generally well tolerated with reversible side effects, and is effective for the treatment of advanced, refractory CTCL.

Bexarotene-Induced T-Cell Immunomodulation and Response in CTCL.

Bexarotene appears to have a profound in vivo T-cell immunomodulatory effect in patients with CTCL pts and the importance of these immune effects for clinical response vis-a-vis direct induction of apoptosis in C TCL needs to be further studied.

Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.

  • M. Duvic
  • Medicine, Biology
    Clinical lymphoma
  • 2000
DAB(389)IL-2 has given complete or partial remission in 30% of highly refractory patients with extensive plaques and disfiguring tumors, and new combination treatment algorithms can be tested to achieve maximal benefit and quality of life for these patients.

Emerging drugs in cutaneous T-cell lymphomas

  • R. Dummer
  • Biology, Medicine
    Expert opinion on emerging drugs
  • 2005
Skin-directed therapies using topical formulations are the preferred first-line modalities for cutaneous lesions in early stages and in this field there are interesting developments using topical retinoids and gene therapy products, such as adeno-IFN-γ.